Dysregulated Mitochondrial Dynamics and Metabolism in Obesity, Diabetes, and Cancer

Wenting Dai¹ and Lei Jiang¹,²*

¹ Department of Molecular and Cellular Endocrinology, Diabetes and Metabolism Research Institute, Duarte, CA, United States, ² Comprehensive Cancer Center, City of Hope Medical Center, Duarte, CA, United States

Metabolism describes the life-sustaining chemical reactions in organisms that provide both energy and building blocks for cellular survival and proliferation. Dysregulated metabolism leads to many life-threatening diseases including obesity, diabetes, and cancer. Mitochondria, subcellular organelles, contain the central energy-producing metabolic pathway, the tricarboxylic acid (TCA) cycle. Also, mitochondria exist in a dynamic network orchestrated by extracellular nutrient levels and intracellular energy needs. Upon stimulation, mitochondria undergo consistent interchange through fusion (small to big) and fission (big to small) processes. Mitochondrial fusion is primarily controlled by three GTPases, mitofusin 1 (Mfn1), Mfn2, and optic atrophy 1 (Opa1), while mitochondrial fission is primarily regulated by GTPase dynamin-related protein 1 (Drp1). Dysregulated activity of these GTPases results in disrupted mitochondrial dynamics and cellular metabolism. This review will update the metabolic roles of these GTPases in obesity, diabetes, and cancer.

Keywords: energy metabolism, TCA cycle, mitochondrial dynamics, GTPase, mdivi-1

INTRODUCTION

The word mitochondrion comes from the Greek words mitos (thread in English) and chondrion (granule in English) (1). The field of mitochondrial dynamics has a history of over 100 years (1–3). In 1914, Mrs. and Mr. Lewis published “Mitochondria in Tissue Culture” as a special article in Science (2) and stated, “The mitochondria are almost never at rest, but are continually changing their position and also their shape.” The full picture of mitochondrial dynamics includes fusion, fission, transportation, and degradation, which have been covered in other reviews (1, 4–6). Mitochondria exist widely in most eukaryotic organisms and have a double membrane structure. The outer mitochondrial membrane contains large quantities of integral membrane proteins called porins, which form channels allowing for small molecules to freely diffuse from one side of the membrane to the other. In contrast, the inner mitochondrial membrane is highly impermeable, even to small metabolites. Three mitochondrial membrane–located GTPases regulate the mitochondrial fusion process, among which Mfn1 and Mfn2 control outer mitochondrial membrane fusion (7), while Opa1 regulates inner mitochondrial membrane fusion (8–10). In contrast, the cytosol-located GTPase Drp1 mediates the mitochondrial fission process (11). Mutations of these GTPases are closely related to human disease, such as Charcot–Marie–Tooth disease type 2A (12) and optic atrophy (13, 14). In this review, we primarily focus on these small GTPases and their influences on metabolic alterations in obesity, diabetes, and cancer.
SMALL GTPASES CONTROL MITOCHONDRIAL FUSION AND FISSION

Mfn1 and Mfn2, homologs of the drosophila protein fuzzy onion (Fzo) (15), are the first reported mammalian GTPases to mediate mitochondrial fusion (16, 17). Mice lacking Mfn1 or Mfn2 are embryonically lethal, which suggests their essential role in embryonic development (7, 18). In mouse embryonic fibroblasts (MEFs), Mfn1 or Mfn2 single-knockout results in fragmented mitochondria (7), while Mfn1 and Mfn2 double-knockout completely blocks mitochondrial fusion (18, 19). Conversely, overexpression of either Mfn1 or Mfn2 can rescue the mitochondrial function (7). These genetic studies show that Mfn1 and Mfn2 have redundant and collaborative roles in mitochondrial fusion.

Opal1 is named after a neurogenic disease optic atrophy. Patients with mutant Opal1 have degenerated retinal ganglion cells and atrophy of the optic nerve (13, 14). Opal1 is the mammalian ortholog of Mgm1, which is essential for mitochondrial fusion in yeast (20, 21). Opal1 is encoded by a complicated set of at least eight mRNA splice forms, and each long Opal1 forms (L-Opal1) peptides that can be further cleaved into short forms (S-Opal1) by proteases Yeast Mitochondrial Escape 1 Like 1 ATPase (YME1L1) and metalloendopeptidase Oma1 (22, 23). YME1L1 and Oma1 double-knockout MEFs only contain L-Opal1 (24). Importantly, YME1L1 and Oma1 establish a near-balance of L-Opal1 and S-Opal1 under basal conditions, and they regulate this balance in response to metabolic changes or mitochondrial dysfunction (24–26). Moreover, the distinction between L-Opal1 and S-Opal1 lies in their different locations within mitochondria, namely, L-Opal1 in the inner mitochondrial membrane and S-Opal1 within the mitochondrial matrix. Consistent with their respective locations, L-Opal1 promotes mitochondrial inner membrane fusion, while S-Opal1 enhances mitochondrial fission (27).

Drp1, a cytosolic protein, plays a crucial role in regulating mitochondrial fission (4). A newborn girl with a dominant-negative mutation in Drp1 had abnormal brain development and several other diseases, which were associated with a severe defect in the fission of both mitochondria and peroxisomes (28). Drp1 knockout mice also exhibit abnormal brain development and die around day 12 of embryonic development (29, 30). Upon activation, Drp1 relocates to the outer mitochondrial membrane and forms a ring structure to constrict mitochondrion. This translocation of Drp1 is regulated by several outer mitochondrial membrane proteins, including fission protein 1 (Fis1), mitochondrial fission factor (Mff), and mitochondrial dynamics proteins of 49 and 51 kDa (MiD49 and MiD51) (31, 32). In mammals, overexpression of Fis1 in mammalian cells promotes mitochondrial fission, while inhibition of Fis1 results in elongation (fusion) (33–35). Knockdown of Mff results in mitochondrial elongation in mammalian cells (35) and reduces the amount of Drp1 recruited to mitochondria (36). In 2011, Palmer et al. reported that a double knockdown of MiD49 and MiD51 leads to mitochondrial elongation and reduces recruitment of Drp1 to mitochondria (37). Subsequently, MiD49 and MiD51 proteins were found to promote mitochondrial fission independent of both Fis1 and Mff (31, 38). Furthermore, the activity of Drp1 could be controlled by its phosphorylation. The cyclin-dependent Drp1 phosphorylation at serine 585 (S585) is essential to promote mitochondrial fission in mitotic cells (39). The cyclic adenosine monophosphate (cAMP)-dependent protein kinase (PKA)–dependent Drp1 phosphorylation at S656 inhibits mitochondrial fission, and the calcineurin-dependent dephosphorylation of Drp1–S656 promotes mitochondrial fragmentation (40). Furthermore, mitogen-activated protein kinase 1 (MAPK1, also known as Erk2)–dependent Drp1 phosphorylation at S616 activates Drp1 and promotes mitochondrial fission (41, 42). In HeLa cells, Drp1 was found to be phosphorylated by protein kinase A (PKA) at S637, and this phosphorylation attenuated the Drp1 GTPase activity (43). Besides, calcineurin-dependent dephosphorylation of Drp1 at the S637 site drives its translocation to mitochondria and promotes mitochondrial fission (44). Genetical and chemical inhibition of Drp1 both result in elongated mitochondria (45).

IMBALANCED MITOCHONDRIAL METABOLISM RESULTS IN OBESITY AND DIABETES

Given the essential role of mitochondria in energy metabolism, mitochondrial dysfunction acts as a key regulator in the pathophysiology of obesity and diabetes. Mutations in some mitochondrial genes have been demonstrated to be the main causes of these metabolic diseases, such as Charcot–Marie–Tooth disease (Mfn2 mutation) and dominant optic atrophy (Opal1 mutation) (4). Interestingly, imbalanced mitochondrial metabolism induced by mitochondrial proteins (especially mitofusins, Opal1, and Drp1) in various tissues has been implicated in the pathology of metabolic diseases (Table 1).

In particular, type 2 diabetes (T2D) is related to the reduced expression of Mfn2, which depresses oxidative phosphorylation (OXPHOS) and impairs mitochondrial fusion in skeletal muscle (46, 76). Also, liver and skeletal muscle deletion of Mfn2 in mice both result in fragmented mitochondrial networks and numerous metabolic abnormalities, including glucose intolerance and enhanced hepatic gluconeogenesis (47, 54). These confirm the crucial regulatory role of Mfn2 in insulin signaling and glucose homeostasis associated with obesity and T2D. Besides, it was first reported that proopiomelanocortin (POMC)–specific ablation of Mfn2 results in endoplasmic reticulum (ER) stress–induced leptin resistance and decreased energy expenditure for protection against obesity (49). Moreover, Mfn1 deficiency leads to a highly fragmented mitochondrial network and enhanced mitochondrial respiration capacity in the myocardium (53) and liver (54) in diabetes. Interestingly, the liver from Mfn1 knockout mice demonstrates a preference for using lipids as the main energy source and a more active complex I to protect against insulin resistance (54). Also during the fast-to-fed transition, mice lacking Mfn1 in POMC neurons exhibit defective mitochondrial architecture and flexibility, which results in defective insulin secretion and abnormal glucose homeostasis by pancreatic β cells (56). Mfn2, but not Mfn1, deletion in brown.
| GTPase | Alterations in expression | Tissue or cell | Mitochondrial metabolism | References |
|--------|---------------------------|---------------|--------------------------|------------|
| Mfn2   | Reduced expression in obese subjects and T2D patients | Skeletal muscle cells | Reduce OXPHOS | (46, 47) |
|        | Mfn2 knockout rat | Skeletal muscle cells | Reduce OXPHOS | (48) |
|        | Mfn2 overexpression rat | Skeletal muscle cells | Enhance OXPHOS | (49) |
|        | Mfn2 knockout mice | POMC neurons | Reduce OXPHOS | (49) |
|        | Mfn2 knockout mice | Liver | Reduce OXPHOS and respiratory rate | (50) |
|        | Mfn2 knockout mice | Brown adipose tissue | Reduce OXPHOS but enhance fatty acid oxidation in female mice | (51, 52) |
| Mfn1   | Reduced expression in diabetic patients | Heart and myocardial | Reduce OXPHOS in glucose utilization but increase fatty acid utilization | (53) |
|        | Mfn1 knockout mice | Liver | Enhance lipid oxidation but not glucose oxidation | (54) |
|        | Reduced expression in male mice | Skeletal muscle cells | Reduce OXPHOS | (55) |
|        | Mfn1 knockout mice | Brown adipose tissue | No effect on energy expenditure | (56) |
|        | Mfn1 knockout mice | POMC neurons | Reduce OCR and energy expenditure; defective insulin secretion and abnormal glucose homeostasis | (56) |
| Opa1   | Opa1 knockdown cell | Adipose tissue and 3T3-L1 adipocytes | Reduce lipolysis and glycerol release by regulating phosphorylation of perilipin 1 | (57) |
|        | Opa1 knockdown mice | Skeletal muscle cells | Reduce OXPHOS and destabilize the respiratory chain supercomplexes | (58) |
|        | Opa1 knockdown mice | Skeletal muscle cells | Reduce OXPHOS | (59) |
|        | Opa1 knockout mice | Skeletal muscle cells | Impair mitochondrial respiratory capacity and disrupt lipid metabolism | (60) |
|        | Higher expression in ad libitum feeding dog | Adipose tissue | Enhance OXPHOS | (61) |
|        | Opa1 knockout mice | Pancreatic β cells | Reduce OXPHOS, glucose-stimulated ATP production, and insulin secretion | (62) |
|        | Opa1 knockdown cell | Cardiomyocyte | Reduce OXPHOS and intracellular ATP levels | (63) |
| Drp1   | Overexpression of Drp1 | Skeletal muscle cells | No deficiency in mitochondria bioenergetics | (64) |
|        | Deletion of Drp1 | Skeletal muscle cells | Enhance oxidative metabolism and uncoupling of OXPHOS | (65) |
|        | Decrease in Drp1 S616 phosphorylation in obese subjects after exercise or in mice | Skeletal muscle cells | Reduce ATP production but increase fat oxidation and insulin sensitivity | (66) |
|        | Drp1 knockdown genetically or pharmacological inactivation by mdv1-1 | Human and mouse pancreatic β cells | Not directly impair glucose-stimulated OXPHOS, but instead limit mitochondrial ATP synthesis by compromising substrate delivery upstream of mitochondria | (67) |
|        | Drp1 pharmacological inactivation by mdv1-1 | Diabetes-susceptible cybrid cells | Enhance OXPHOS and insulin-mediated glucose uptake | (68) |
|        |                    | 3T3-L1 adipocytes | Not affect ROS production, lipid accumulation, or lipid metabolism | (68) |
|        | Drp1 knockout mice | Pancreatic β cells | Normal OCR, but significantly reduce second-phase insulin secretion and glucose-stimulated amplification of insulin secretion | (69) |
|        | Drp1 knockout mice | Skeletal muscle cells | Enhance insulin signaling and systemic insulin sensitivity | (65, 66, 70) |
|        |                      | Skeletal muscle cells | Reduce activities of complexes I and III | (71) |
|        |                      | Liver | Enhance energy expenditure | (72) |
|        |                      | POMC neurons, dorsal vagal complex | Increase ROS content, leptin sensitivity, and glucose responsiveness | (73, 74) |
|        | Overexpression of Drp1 | Diabetes-susceptible cybrid cells | Increase mitochondrial ROS; reduce IRS1–AKT pathway and GLUT translocation | (75) |

OXPHOS, oxidative phosphorylation; Mfn1 and 2, mitofusin 1 and 2; Opa1, optic atrophy 1; L-Opa1, long Opa1; S-Opa1, short Opa1; Drp1, dynamin-related protein 1; POMC, proopiomelanocortin; ROS, reactive oxygen species; OCR, oxygen consumption rate; GLUT, glucose transporter; T2D, type 2 diabetes; mdv1-1, mitochondrial division inhibitor 1; ATP, adenosine triphosphate; IRS, insulin receptor substrate 1; AKT, serine/threonine-specific protein kinase.
adipose tissue (BAT) remodels the mitochondrial dysfunction, leading to an increase in insulin sensitivity and resistance to obesity (51, 52, 77). These observations have implicated a crucial role of mitofusins in the control of mitochondrial energy metabolism and insulin resistance. However, further studies should determine the distinct regulatory mechanisms of Mfn1 and Mfn2 targeting mitochondrial metabolism in diabetes and obesity.

The expanding evidence also displays the involvement of Opa1 in obesity and diabetes. With regard to adiposity, Opa1 has been reported to be involved in regulating lipolysis by anchoring a pool of PKA that phosphorylates perilipin and thereby triggers lipolysis in vitro (57) and in vivo (61). Further studies show the translocation of Opa1 from mitochondria to lipid droplets during human adipocyte differentiation (78). Proteases YME1L1 and Oma1 can cleave L-Opa1 into S-Opa1 (79). The deficiency of Oma1 perturbs the mitochondrial fusion–fission equilibrium, thereby reducing OXPHOS, enhancing fatty acid oxidation and decreasing energy expenditure, all of which collaboratively induce obesity in mice (79). Moreover, Opa1 deletion in pancreatic β cells impairs glucose-stimulated adenosine triphosphate (ATP) production and insulin secretion, which subsequently develops into hyperglycemia (62). Also, insulin increases Opa1 levels and promotes mitochondrial fusion in cardiomyocytes, which enhances OXPHOS, whereas Opa1 deletion suppresses the insulin-stimulated ATP synthesis (63). A recent study reported that sedentary but not active humans display an age-related decline in Opa1, which is associated with muscle loss (58). Acute muscle-specific deletion of Opa1 induces muscle inflammation, ER stress, and secretion of fibroblast growth factor 21 (FGF21) (58–60). Apart from these, a recent study addressed the physiological relevance of the concomitant impairment of mitochondrial fusion and fission machinery (80). These confirm the close relationship between Opa1 and mitochondrial insulin-stimulated energy metabolism, which provides a basis for its regulatory role in obesity and diabetes. Therefore, it is urgent to elucidate how Opa1 processing regulates mitochondrial metabolism in obesity and diabetes.

The mitochondrial fission machinery protein Drp1 is also involved in obesity and T2D through its effect on the rate of mitochondrial oxidative metabolism. Drp1-mediated mitochondrial fission results in mitochondrial fragmentation along with decreased ATP content, which further leads to reduced insulin-mediated glucose uptake in human skeletal muscle (66) and significant loss of glucose-stimulated insulin secretion in mouse pancreatic β cells (69). Also in pancreatic β cells, Drp1 deletion largely impairs glucose-stimulated insulin secretion without affecting oxygen consumption and intracellular calcium mobilization (69). On the contrary, Drp1 regulates insulin secretion via glucose-fueled respiration, and pyruvate completely rescues the impaired insulin secretion of fission-deficient β cells (67). These data appear inconsistent, and the regulatory machinery of Drp1 affecting insulin secretion requires further clarification. When used to treat mice, mitochondrial division inhibitor 1 (mdivi-1), a Drp1 inhibitor, rescues tubular mitochondrial network and membrane potential, decreases oxidative stress, and increases insulin-mediated glucose uptake in diabetes-susceptible hybrid cells (68). However, the inhibition of Drp1 by mdivi-1 has no effect on reactive oxygen species (ROS) production, lipid accumulation, or the expression of adipogenic-related proteins in differentiated 3T3-L1 adipocytes (75). In contrast, overexpression of Drp1 decreases mitochondrial network formation and increases mitochondrial ROS, subsequently suppressing the insulin receptor substrate 1 (IRS1) – serine/threonine-specific protein kinase (AKT) pathway and glucose transporter (GLUT) translocation stimulated by insulin (68). Also, the depressed phosphorylation of Drp1 at S616 in skeletal muscle is negatively correlated with enhancement in fat oxidation and insulin sensitivity (66), which is further supported by the observation that Drp1 deletion induced aberrant mitochondrial fission, improving insulin signaling and systemic insulin sensitivity in skeletal muscle of obese mice (70). Moreover, Drp1 deficiency reduces fat mass, induces ER stress, and promotes energy expenditure through increasing the expression of FGF21 in the liver, which helps mice fed with a high-fat diet to be protected against obesity (72). Mice lacking Drp1 in skeletal muscle develop a lethal mitochondrial myopathy, and this muscle-specific Drp1 deletion impairs mitochondrial function, including the reduced activities of complexes I and III (71). In contrast, Drp1 overexpression in skeletal muscle displayed a drastic impairment in postnatal muscle growth, with reorganization of the mitochondrial network and reduction of mitochondrial DNA (mtDNA) quantity, without the deficiency of mitochondrial bioenergetics (64). Muscle-specific Drp1 heterozygote mice have impaired muscle endurance and running performance (65). The impaired mitochondrial remodeling induced by Drp1 in skeletal muscle is also associated with derangements in metabolism and insulin sensitivity (65, 66). Additionally, inducible deletion of Drp1 in POMC neurons (73) and the dorsal vagal complex (DVC) (74) increases ROS content, leptin sensitivity, and glucose responsiveness. Thus, Drp1-mediated mitochondrial fission may underlie the pathogenesis of insulin resistance in obesity and T2D. However, further studies are required to explore potential mechanisms for therapeutic interventions.

**MITOCHONDRIAL FUSION AND FISSION SHAPE CANCER METABOLISM**

Most studies of the cancer-related mitochondrial dynamics focus on their functions in apoptosis, which have been well-reviewed (1, 6). Therefore, here we focus on energy metabolism in cancer, another important function of mitochondria (Table 2). Cancer metabolism also has a history of about 100 years. In 1925, Dr. Otto Warburg first described that cancer cells tend to favor metabolism via aerobic glycolysis rather than the much more efficient OXPHOS pathway, which is widely known as the “Warburg effect” (93–96). Although Dr. Warburg hypothesized that dysfunctional mitochondria were the source of anaerobic glycolysis, more recent studies found that cancer cells often have intact mitochondrial metabolism (97, 98).
Mitochondrial morphology undergoes a dynamic balance between fusion and fission in response to the altered extracellular nutrient level (5). Meanwhile, cancer metabolism is also known for its flexibility to the surrounding nutrient composition (99), and cancer cells acquire different metabolic programs corresponding to their development stages. Rapid proliferating cancer cells have a high glycolytic activity and fatty acid synthesis rate, which provide the building blocks for cell growth. Metastatic cancer cells have high oxidative metabolism, which maintains the energy need for mobility (101, 102). In general, oxidative metabolism is less active in the fragmented mitochondria when compared to the tubular mitochondria. Limited mitochondrial oxidation preserves glycolytic intermediates, which can be used as the building blocks for cancer cell proliferation. The highly activated glycolysis has been linked to mitochondrial fission in many types of cancer, including lung cancer (103), metastatic breast cancer (104), ovarian cancer (105), colorectal cancer (106, 107), pancreatic cancers (41), and melanoma (42). In the meantime, active oxidative metabolism has also been connected to mitochondrial fusion in some metastatic cancer models, including pancreatic cancer (108).

**TABLE 2** | The role of GTPases in cancer metabolism.

| GTPase | Approach | Cancer type | Mitochondrial metabolism | References |
|--------|----------|-------------|--------------------------|------------|
| Mfn2   | Knockdown | Lung        | Induce sucrase metabolism | (81)       |
|        | Knockdown | Ovarian     | Reduce OCR                | (82)       |
|        | Knockdown | Breast      | Reduce OCR                | (83)       |
|        | Knockdown | Melanoma    | Reduce OCR                | (84)       |
|        | Knockdown | Pancreatic  | Enhance mitochondrial metabolism | (85) |
|        | Knockout  | Liver       | Reduce OXPHOS; enhance lipid metabolism | (86) |
| Mfn1/2 | Knockdown | iPSCs       | Reduce ATP content        | (87)       |
|        | 17β-estradiol | Breast | Increase ATP content | (88) |
| Opa1   | Overexpression | MAFs    | Enhance ATP synthase oligomerization | (89) |
|        | IF1 mutation | Cervical | Reduce OCR                | (90)       |
| Drp1   | S637A mutation | Liver | Reduce OCR                | (91)       |
|        | Knockdown  | Brian       | Reduce OCR                | (92)       |
|        | Knockdown  | Melanoma    | Increase OCR              | (42)       |
|        | Knockdown  | Kidney      | Reduce maximal OCR        | (41)       |
|        | Knockdown  | Melanoma    | Maintain OCR              | (84)       |
|        | mdivi-1   | Melanoma    | Maintain OCR              | (84)       |
|        | mdivi-1   | Breast      | Increase OCR              | (83)       |

IPSCs, induced pluripotent stem cells; MAFs, mouse adult fibroblasts; IF1, inhibitory factor 1.

Mfn1/2 shows altered expression in human tumors (109, 110). Lower Mfn2 expression is observed in breast cancer (111), lung cancer (103), urinary bladder cancers (112), hepatocellular carcinoma (113), colorectal cancer (106), and gastric cancer (114), compared to the normal tissue. In line with the lower Mfn2 expression in cancer, several studies demonstrate that Mfn2 overexpression inhibits cancer cell proliferation and colony formation and weakens the invasion and migratory ability (106, 114–116). It is worth noting that the higher expression of Mfn2 has also been reported in lung adenocarcinoma tissues as compared to adjacent normal tissues, and Mfn2 knockdown results in impaired cancer cell proliferation (81). In ovarian cancer (82), breast cancer (83), and melanoma (84), Mfn2 knockdown suppresses oxygen consumption rate (OCR). In pancreatic cancer cells (PANC-1), Mfn2 knockdown enhances mitochondria-dependent energy metabolism by promoting activity of electron transport chain complexes (85). Besides, Mfn2 knockdown induces mitochondrial biogenesis and elevates OXPHOS in Ras-transformed mice fibroblasts (117). A recent study reported that liver-specific ablation of Mfn2 in mice provoked inflammation, triglyceride accumulation, fibrosis, and liver cancer (86). As both knockdown and overexpression of Mfn2 impair cancer cell survival in certain cancer types, further studies need to further explore the different roles of Mfn2 in various tumor types.

Opa1 and its proteolytic processing are important to maintain mitochondrial fusion. Studies have displayed a significant decrease in the expression of Opa1 along with high mitochondrial fragmentation in hepatocellular carcinoma (118). Tumor suppressor p53 is involved in Oma1-mediated L-Opa1 processing and mitochondrial fragmentation in ovarian and cervical cancer cells (119), the role of which is further supported by the close relationship between S-Opa1 and the p53 signaling pathway (120). Interestingly, in mouse adult fibroblasts (MAFs), Opa1 interacts with mitochondrial F1F0-ATP synthase, favors ATP synthase oligomerization, and finally, protects mitochondria from respiratory chain inhibition by modulating cristae shape (89). Subsequent studies have discovered that the ATPase inhibitory factor 1 (IF1), a mitochondrial protein, prevents apoptotic remodeling of mitochondria by inhibiting Oma1 activation and Opa1 processing in HeLa cells, which further decreases OCR and intracellular ATP synthesis (90). Furthermore, Oma1 is dependent on the IF1 protective activity against apoptotic processing of Opa1 in HeLa cells (90). These observations display an essential role of ATP synthase in Opa1 processing to ensure normal mitochondrial bioenergetics. Since Opa1 processing complicates its function in maintenance of mitochondrial metabolism, future studies are required to focus more on the distinct regulatory machinery of Opa1 and its processing involved in mitochondrial metabolism within various cancer cells. This will provide insights into anti-tumor pharmaceutical therapy targeting Opa1-regulating mitochondrial metabolism.

Drp1 expression and activity have been associated with mitochondria fragmentation, which facilitates glycolysis in cancer cells. High Drp1 expression has been detected in lung cancer (103), breast cancer (104), thyroid cancer (121),
glio-blastoma (92), and hepatocellular carcinoma (91). In 2015, two back-to-back studies demonstrated the essential role of Drp1 activation in MAPK-driven tumor growth (41, 42). Moreover, Drp1 can be activated and phosphorylated by extracellular signal-regulated kinase (ERK1/2) on S616, which is required for Ras-induced transformation in MEFs (42). This S616 phosphorylation and mitochondrial fragmentation is enhanced in human pancreatic cancer (41) and brain tumor initiating cells (BTICs) (92). Similarly, the inhibition of Erk signaling promotes mitochondrial fusion and increases mitochondrial metabolism but reduces the Drp1 activity in A375, SK-MEL-28, and BT-474 cells (42). On the contrary, the reduced expression of Drp1 exerts different effects on oxidative metabolism in different cells. For instance, Drp1 knockdown increases OCR and promotes ATP production in Ras-transformed MEFs and the SK-MEL-28 cells (42). However, Drp1 knockdown decreases the maximal OCR in the HRas-transformed HEK-TtH cells (41) and in the T387 BTICs (92), which further prevents cell growth and tumor formation. A recent study shows that in lung cancer cells, sirtuin 4 (SIRT4, a nicotinamide-adenine dinucleotide+ (NAD+)-dependent protein deacetylase) inhibits Drp1 phosphorylation at the S616 site and weakens Drp1 recruitment to the mitochondrial membrane via an interaction with Fis1 (122). Besides, Drp1 can also be phosphorylated on S637, which subsequently represses its activity and mitochondrial translocation. Particularly, S637-mediated mitochondrial elongation under energy stress is essential for hepatocellular carcinoma cell survival both in vitro and in vivo (91). Interestingly, lung cancer cell lines have higher S616 and lower S637 phosphorylation, when compared to human bronchial epithelial cell (hBEC) (103).

Mdivi-1 is widely used as a Drp1 inhibitor (30, 123). In 2008, Dr. Nunnari’s group first utilized mdivi-1 to study mitochondrial dynamics (45), and most of the studies have followed this application of mdivi-1 to examine the metabolic role of Drp1. mdivi-1 treatments result in both increased and decreased OCR, depending on different cell types. In most conditions, mdivi-1 treatment induces mitochondrial fusion and increases mitochondrial activity, which further enhances OCR (124). In MDA-MB-231 cells and H1299 cells, mdivi-1 treatment significantly depresses OCR, without changing the cellular ATP level (125). Interestingly, a study shows that mdivi-1 represses OCR to a similar degree in both wild-type and Drp1 knockout MEF cells (126). This Drp1-independent role of mdivi-1 is further supported by the finding that mdivi-1 works as mitochondrial complex I inhibitor, to induce ROS and repress OCR (126). In the highly oxidative estrogen receptor–positive breast cancer cells, mdivi-1 reduces cellular mitochondrial bioenergetics and increases glycolysis without any influence on mitochondrial morphology (127). Overall, mdivi-1 has potential therapeutic avenues in suppressing tumor progression. Further studies are required to explore its effects on the oxidative metabolic alterations in cancer.

**SUMMARY**

Dysregulated metabolism is a common feature of the metabolic diseases, including obesity, diabetes, and cancer, which can be regulated by mitochondrial dynamics (Figure 1). Obese and diabetic patients have pathology in multiple tissues, such as fat, muscle, liver, kidney, and pancreas. Cancer patients also have tumors from different origins, and all cancer types undergo different stages. Moreover, the specific mitochondrial dynamics under these pathology conditions are in response to different metabolic states, and thus, it is important to discuss the mitochondrial dynamics and metabolism in a context-dependent manner. For example, mild nutrient deprivation induces mitochondrial fusion and increases energy-producing efficiency to compensate the energy demand for growth, while severe nutrient deprivation drives mitochondrial fission and promotes cell apoptosis to preserve energy for neighboring cells. As demonstrated here, the GTPases (Mfn1, Mfn2, Opa1, and Drp1) have strong regulatory effects in balancing mitochondrial fusion and fission, and these GTPases control the aforementioned metabolic diseases predominantly through orchestrating oxidative metabolism. It is essential to explore how the GTPases orchestrate metabolic alterations under certain nutrient environments. Since mitochondrial morphology undergoes a dynamic process balanced by the above GTPases, knockdown and knockout of these result in abnormal chronic inhibition and can potentially cause indirect metabolic effects. Therefore, it is important to develop new chemical inhibitors to acutely block the function of these GTPases. Oxygen consumption is only a small
fraction in metabolism, and more direct metabolomics and metabolic flux analyses will provide a clearer picture of the mitochondrial dynamics and metabolism in obesity, diabetes, and cancer.

**AUTHOR CONTRIBUTIONS**

LJ designed the review. WD made the figure and tables. WD and LJ wrote the review.

**REFERENCES**

1. Archer SL. Mitochondrial dynamics—mitochondrial fusion and fission in human diseases. *N Engl J Med.* (2013) 369:2236–51. doi: 10.1056/NEJMra1215233.

2. Lewis MR, Lewis WH. Mitochondria in tissue culture. *Science.* (1914) 39:330–3. doi: 10.1126/science.39.1000.330.

3. Lewis MR, Lewis WH. Mitochondria (and other cytoplasmic structures) in tissue cultures. *Am J Anat.* (1915) 17:339–401. doi: 10.1002/aja.1000170304.

4. Chan DC. Fusion and fission: interlinked processes critical for mitochondrial health. *Annu Rev Genet.* (2012) 46:265–87. doi: 10.1146/annurev-genet-110410-132529.

5. Chen H, Chan DC. Mitochondrial dynamics in regulating the unique phenotypes of cancer and stem cells. *Cell Metab.* (2017) 26:39–48. doi: 10.1016/j.cmet.2017.05.016.

6. Westermann B. Mitochondrial fusion and fission in cell life and death. *Nat Rev Mol Cell Biol.* (2010) 11:572–84. doi: 10.1038/nrm3013.

7. Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. *J Cell Biol.* (2003) 160:189–200. doi: 10.1083/jcb.200211046.

8. Cipolat S, Martins de Brito O, Dal Zilio B, Scorrano L. OPA1 requires mitofusin 1 to promote mitochondrial fusion. *Proc Natl Acad Sci USA.* (2004) 101:15927–32. doi: 10.1073/pnas.040743101.

9. Song Z, Ghochani M, McCaffery JM, Frey TG, Chan DC. Mitofusins and OPA1 mediate sequential steps in mitochondrial membrane fusion. *Mol Biol Cell.* (2009) 20:3525–32. doi: 10.1091/mbc.E09-03-0252.

10. Misha P, Carelli V, Manfredi G, Chan DC. Proteolytic cleavage of Opa1 stimulates mitochondrial inner membrane fusion and couples fusion to oxidative phosphorylation. *Cell Metab.* (2014) 19:630–41. doi: 10.1016/j.cmet.2014.03.011.

11. Frank S, Gaume B, Bergmann-Leitner ES, Leitner WW, Robert EG, Catez F, et al. The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. *Dev Cell.* (2001) 1:515–25. doi: 10.1016/s1534-5807(01)00055-7.

12. Zuchner S, Merzhanova IV, Mughia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot–Marie–Tooth neuropathy type 2A. *Nat Genet.* (2004) 36:449–51. doi: 10.1038/ng1341.

13. Alexander C, Votruba M, Pesch UEA, Thiselton DL, Mayer S, Moore A, et al. OPA1, encoding a mitochondrial dynamin-related GTPase, is mutated in dominant optic atrophy linked to chromosome 3q28. *Nat Genet.* (2000) 26:221. doi: 10.1038/79944.

14. Delettre C, Lenaers G, Grifoñin J-M, Gigarel N, Lorenzo C, Belenguer P, et al. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. *Nat Genet.* (2000) 26:207. doi: 10.1038/79936.

15. Hales KG, Fuller MT. Developmentally regulated mitochondrial fusion mediated by a conserved, novel, predicted GTPase. *Cell.* (1997) 90:121–9. doi: 10.1016/S0092-8674(00)80319-0.

16. Santel A, Fuller MT. Control of mitochondrial morphology by a human mitofusin. *J Cell Sci.* (2001) 114:867–74.

17. Legros F, Lombez A, Frachon P, Rojo M. Mitochondrial fusion in human cells is efficient, requires the inner membrane potential, and is mediated by mitofusins. *Mol Biol Cell.* (2002) 13:4343–54. doi: 10.1091/mbc.e02-06-0330.

**FUNDING**

Research reported in this publication was also supported by the National Cancer Institute of the National Institutes of Health under award number P30CA33572.

**ACKNOWLEDGMENTS**

We would like to apologize to those colleagues whose work could not be cited or discussed in sufficient detail due to space limitations.
34. Stojanovski D, Koutsopoulos OS, Okamoto K, Ryan MT. Levels of human Fis1 at the mitochondrial outer membrane regulate mitochondrial morphology. J Cell Sci. (2004) 117(Pt 7):1201–10. doi: 10.1242/jcs.01058

35. Gandre-Babbe S, van der Bliek AM. The novel tall-anchored membrane protein Mff controls mitochondrial and peroxisomal fission in mammalian cells. Mol Biol Cell. (2008) 19:2402–12. doi: 10.1091/mbc.E07-12-1287

36. Otera H, Wang C, Cleland MM, Setoguchi K, Yokota S, Youle RJ, et al. Mitofusin 2, the Charcot–Marie–Tooth neuropathy type 2A gene product, Mfn2, up-regulates fuel oxidation of skeletal muscle: effects of type 2 diabetes, obesity, weight loss, and the mitochondrial dynamics and bioenergetics in diabetic skeletal muscle. PLoS ONE. (2014) 9:e92810. doi: 10.1371/journal.pone.0092810

37. Palmer CS, Osellame LD, Laine D, Koutsopoulos OS, Frazier AE, Ryan MT. Levels of Drp1, the dynamin-related GTPase Defp1 participates in mitochondrial fission. J Biol Chem. (2007) 282:11521–9. doi: 10.1074/jbc.M607279200

38. Palmiter CS, Elgass KD, Parton RG, Osellame LD, Stojanovski D, Ryan MT. Phosphorylation of Drp1 regulates its GTPase activity and mitochondrial fission and fusion. J Biol Chem. (2009) 284:27584–93. doi: 10.1074/jbc.M1083789783

39. Taguchi N, Ishihara N, Jofuku A, Oka T, Mihara K. Mitotic phosphorylation of dynamin-related GTPase Drp1 regulates mitochondrial fission. J Cell Biol. (2015) 209:537–51. doi: 10.1083/jcb.201501.002

40. Grego-Rodriguez CA, Vázquez-Sánchez CA, Calvo-Sánchez CA, et al. Critical reappraisal confirms that mitofusin 1 is an A-kinase anchoring protein on lipid droplets that mediates adrenergic control of lipolysis. EMBO J. (2013) 32:1646–56. doi: 10.1038/emboj.2013.5

41. Cribbs JT, Strack S. Reversible phosphorylation of Drp1 by cyclic AMP–dependent protein kinase and calcineurin regulates mitochondrial fission and cell death. EMBO Rep. (2007) 8:939–44. doi: 10.1038/sj.embor.7401062

42. Nascimento A, Mylius LJ, She A, Byrne FL, Hoehn KL, et al. Phosphorylation and nuclear translocation of Mfn2 promotes mitochondrial fission and MAPK-driven tumor growth. Mol Cell. (2015) 57:3–12. doi: 10.1016/j.molcel.2015.01.002

43. Chang CR, Blackstone C. Cyclic AMP–dependent protein kinase phosphorylation of Drp1 regulates its GTPase activity and mitochondrial morphology. J Biol Chem. (2007) 282:21538–7. doi: 10.1074/jbc.C700000200

44. Cereghetti GM, Stangerlin A, Martins de Brito O, Chang CR, Blackstone C, Bernardi P, et al. Dephosphorylation by calcineurin regulates translocation of Drp1 to mitochondria. Proc Natl Acad Sci USA. (2008) 105:15803–8. doi: 10.1073/pnas.0808249105

45. Cassidy-Stone A, Chikpin JE, Ingerman E, Song C, Yoo C, Kuwana T, et al. Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev Cell. (2008) 14:193–204. doi: 10.1016/j.devcel.2007.11.019

46. Zorzano A, Liesa M, Palacin M. Mitochondrial dynamics as a bridge between diabetes but not in obese patients. Circulation. (2014) 130:554–64. doi: 10.1161/circulationaha.113.008476

47. Montaigne D, Marechal X, Coisne A, Debry N, Modine T, Fayad G, et al. Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients. Circulation. (2014) 130:554–64. doi: 10.1161/circulationaha.113.008476

48. Bergman J, Palacio M, Zorger I, Munteanu R, Usberti E, et al. Mitochondrial dysfunction mediated by mitofusin 1 is required for POMC neuron glucose–sensing and insulin release control. Cell Metab. (2017) 25:1390–9.e6. doi: 10.1016/j.cmet.2017.05.010

49. Pidoux G, Witzczak O, Jaraessa E, Myrvold L, Urlaub H, Stokka A, et al. Optic atrophy 1 is an A-kinase anchoring protein on lipid droplets that mediates adrenergic control of lipolysis. EMBO J. (2011) 30:4371–86. doi: 10.1038/emboj.2011.365

50. Tezze C, Romanello V, Desbats MA, Fadini GP, Alibero M, Favaro G, et al. Age-associated loss of OPA1 in muscle impacts muscle mass, metabolic homeostasis, systemic inflammation, and epithelial senescence. Cell Metab. (2017) 25:1374–89.e6. doi: 10.1016/j.cmet.2017.04.021

51. Rodriguez-Nuevo A, Díaz-Ramos A, Noguera E, Díaz-Saez F, Duran X, Munoz JR, et al. Mitochondrial DNA and TLR9 drive muscle inflammation upon Opa1 deficiency. EMBO J. (2018) 37:e96553. doi: 10.15252/embj.201796553

52. Pereira RO, Tadinada SM, Zasadny FM, Oliveira KJ, Pires KMP, Oliveira A, et al. OPA1 deficiency promotes secretion of FGF21 from muscle that prevents obesity and insulin resistance. EMBO J. (2017) 36:2126–45. doi: 10.15252/embj.201696179

53. Grant RW, Vester Boler BM, Ridge TK, Graves TK, Swanson KS. Adipose tissue transcriptome changes during obesity development in female dogs. Physiol Genomics. (2011) 43:295–307. doi: 10.1152/physiogenomics.00190.2010

54. Zhang Z, Wakabayashi N, Wakabayashi J, Tamura Y, Song WJ, Sereda S, et al. The dynamin-related GTPase OPA1 is required for glucose-stimulated ATP production in pancreatic beta cells. Mol Biol Cell. (2011) 22:2235–45. doi: 10.1091/mbc.E10-12-0933

55. Parra V, Verdejo HE, Igleski M, Del Campo A, Troncoso R, Jones D, et al. Insulin stimulates mitochondrial fusion and function in cardiomyocytes via the Akt–mTOR–NFκB–Opp1–Drp1 signaling pathway. Diabetes. (2014) 63:75–88. doi: 10.2337/db13-0340

56. Touvier T, De Palma C, Rigamonti E, Scaglione A, Incerti E, Mazelin L, et al. Muscle-specific Drp1 overexpression impairs skeletal muscle growth via translational attenuation. Cell Death Dis. (2015) 6:e1663. doi: 10.1038/cddis.2014.595

57. Moore TM, Zhou Z, Cohn W, Norheim F, Lin AJ, Kalajian N, et al. The impact of exercise on mitochondrial dynamics and the role of Drp1 in exercise performance and training adaptations in skeletal muscle. Mol Metabol. (2019) 21:51–67. doi: 10.1016/j.molmet.2018.11.012

58. Fealy CE, Mulya A, Lai N, Kirwan JP. Exercise training decreases activation of the mitochondrial fission protein dynamin-related protein-1 in insulin-resistant human skeletal muscle. J Appl Physiol. (2014) 117:239–45. doi: 10.1152/japplphysiol.01064.2013

59. Kabra UD, Pfehlmann K, Migliorini A, Keipert S, Lamp D, Korsgren O, et al. Direct substrate delivery into mitochondrial fission-deficient pancreatic islets rescues insulin secretion. Diabetes. (2017) 66:1247–57. doi: 10.2337/db16-1088

60. Lin HY, Weng SW, Chang YH, Su YJ, Chang CM, Tsai CJ, et al. The causal role of mitochondrial dynamics in regulating insulin resistance in diabetes: link through mitochondrial reactive oxygen species. Oxid Med Cell Longev. (2018) 2018:5714383. doi: 10.1155/2018/5714383

61. Hennings TG, Chopra DG, DeLeon ER, VanDeusen HR, Sesaki H, Merrins MJ, et al. In vivo deletion of beta-cell Drp1 impairs insulin resistance and impairs thermogenesis. EMBO Rep. (2017) 18:1123–38. doi: 10.15252/embr.201643827
secretion without affecting islet oxygen consumption. Endocrinology. (2018) 159:3245–56. doi: 10.1210/en.2018-00445
70. Ieng FF, Tsai PJ, Guo SM, Kuo LH, Chang CS, Su IJ, et al. Mitochondrial fission contributes to mitochondrial dysfunction and insulin resistance in skeletal muscle. Mol Cell Biol. (2012) 32:309–19. doi: 10.1128/mcb.05603-11
71. Lin SW, Romanov V, Varani T, Andrea Desbats M, Morbidoni V, Tezze C, et al. DRP1-mediated mitochondrial shape controls calcium homeostasis and muscle mass. Nat Commun. (2019) 10:2576. doi: 10.1038/s41467-019-10226-9
72. Wang L, Ishihara T, Ibayashi Y, Tatsushima K, Setoyama D, Hanada Y, et al. Disruption of mitochondrial fission in the liver protects mice from diet-induced obesity and metabolic deterioration. Diabetologia. (2015) 58:2371–80. doi: 10.1007/s00125-015-3704-7
73. Santoro A, Campolo M, Liu C, Sesaki H, Meli R, Liu ZW, et al. DRP1 suppresses leptin and glucose sensing of POMC neurons. Cell Metabol. (2017) 25:647–60. doi: 10.1016/j.cmet.2017.01.003
74. Filippi BM, Abraham MA, Silva PN, Rasti M, LaPierre MP, Bauer PV, et al. Dynamin-related protein 1-dependent mitochondrial fission changes in the dorsal vagal complex regulate insulin action. Cell Rep. (2017) 18:2301–9. doi: 10.1016/j.celrep.2017.02.035
75. Kim JH, Park SJ, Kim B, Choe YG, Lee DS. Insulin-stimulated lipid accumulation is inhibited by ROS-scavenging chemicals, but not by the Drp1 inhibitor mdivi-1. PLoS ONE. (2017) 12:e0185764. doi: 10.1371/journal.pone.0185764
76. Kelley DE, He J, Menishkova EV, RitoV VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes. (2002) 51:2944–50. doi: 10.2337/diabetes.51.10.2944
77. Scheideler M, Herzig S. Let’s burn whatever you have: mitofusin 2 metabolically re-wires brown adipose tissue. EMBO Rep. (2017) 18:1039–40. doi: 10.15252/embr.201744341
78. Rogné M, Chu DT, Kuntrziger TM, Mylronou MN, Collas P, Tasken K. OPA1-anchored PKA phosphorylates perilipin 1 on S522 and S497 in adipocytes differentiated from human adipose stem cells. Mol Biol Cell. (2018) 29:1487–501. doi: 10.1091/mbc.E17-09-0538
79. Quiros PM, Ramsay AJ, Sala D, Fernandez-Vizarra E, Rodriguez F, Peinado JR, et al. Mitochondrial dynamic alterations regulate melanoma cell progression. J Toxicol Sci. (2018) 43:277–34. doi: 10.2131/jts.43.272
80. Sastre-Serra I, Nadal-Serrano M, Pons DG, Roca P, Oliver J. Mitochondrial dynamics is affected by 17β-estradiol in the MCF-7 breast cancer cell line. Effects on fission and fusion related genes. Int J Biochem Cell Biol. (2012) 44:1901–5. doi: 10.1016/j.biocell.2012.07.012
81. Quintana-Cabrera R, Quirin C, Glytsou C, Corrado M, Urbani A, Pellattiero A, et al. The cristae modulator Optic atrophy 1 requires mitochondrial ATP synthase oligomers to safeguard mitochondrial function. Nat Commun. (2018) 9:2618. doi: 10.1038/s41590-018-0565-x
82. Faccenda D, Nakamura J, Gorini G, Dhoot GK, Picentini M, Yoshida M, et al. Control of mitochondrial remodeling by the ATPase inhibitory factor 1 unveiling a pro-survival relay via OPA1. Cell Rep. (2017) 18:1869–83. doi: 10.1016/j.celrep.2017.01.070
83. Jheng HF, Tsai PJ, Guo SM, Kuo LH, Chang CS, Su IJ, et al. Mitochondrial control by DRP1 in brain tumor initiating cells. Nat Neurosci. (2015) 18:501–10. doi: 10.1038/nn.3960
84. Warburg O. Iron, the oxygen-carrier of respiration-ferment. Science. (1925) 61:575–82. doi: 10.1126/science.61.1588.575
85. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. (1927) 8:519–30.
86. Warburg O. On the origin of cancer cells. Science. (1956) 123:309–14.
87. Otto AM. Warburg effect(s)—a biographical sketch of Otto Warburg and his impacts on tumor metabolism. Cancer Metab. (2016) 4:5. doi: 10.1186/s40170-016-0145-9
88. DeBerardinis RJ, Thompson CB. Cellular metabolism and disease: what do metabolic outliers teach us? Cell. (2012) 148:1132–44. doi: 10.1016/j.cell.2012.02.032
89. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. (2011) 11:85–95. doi: 10.1038/nrc2981
90. Palm W, Thompson CB. Nutrient acquisition strategies of mammalian cells. Nature. (2015) 546:234–42. doi: 10.1038/nature22379
91. Jang L, DeBerardinis RJ. When more is less. Nature. (2012) 489:511. doi: 10.1038/48951a
92. Jang L, DeBerardinis RJ, Boothman DA. The cancer cell ‘energy grid’: TGF-beta1 signaling coordinates metabolism for migration. Mol Cell Oncol. (2015) 2:e931994. doi: 10.7150/mco.2015.931994
93. Jang L, Xiao L, Sugihara H, Huang X, Ali A, Kuro-o M, et al. Metabolic reprogramming during TGFbeta1-induced epithelial-to-mesenchymal transition. Oncogene. (2015) 34:3908–16. doi: 10.1038/onc.2014.321
94. Rehman J, Zhang HJ, Toth PT, Zhang Y, Marsboom G, Hong Z, et al. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J. (2012) 26:2175–86. doi: 10.1096/fj.11-196543
95. Zhao J, Zhang J, Yu M, Xie Y, Huang Y, Wolff DW, et al. Mitochondrial dynamics regulates migration and invasion of breast cancer cells. Oncogene. (2013) 32:4814–24. doi: 10.1038/onc.2012.494
96. Tanwar DK, Parker DJ, Gupta P, Spurlock B, Alvarez RD, Basu MK, et al. Crosstalk between the mitochondrial fission protein, Drp1, and the cell cycle is identified across various cancer types and can impact survival of epithelial ovarian cancer patients. Oncotarget. (2016) 7:60021–37. doi: 10.18632/oncotarget.11047
97. Cheng X, Zhou D, Wei J, Lin J. Cell-cycle arrest at G2/M and proliferation inhibition by adenovirus-expressed mitofusin-2 gene in human colorectal cancer cell lines. Neoplasma. (2013) 60:620–6. doi: 10.4149/ne_2013_080
98. Inoue-Yamauchi A, Oda H. Depletion of mitochondrial fission factor DRP1 causes increased apoptosis in human colon cancer cells. Biochem Biophys Res Commun. (2012) 421:81–5. doi: 10.1016/j.bbrc.2012.10.013
99. Yu M, Huang Y, Deorukhkar A, Fujimoto T, Govindaraju S, Molkentine J, et al. Mitochondrial fission suppresses pancreatic cancer growth via reduced oxidative metabolism. bioRxiv. (2018) 2018.279745. doi: 10.1101/279745
100. Senft D, Ronai ZA. Regulators of mitochondrial dynamics in cancer. Curr Opin Cell Biol. (2016) 39:43–52. doi: 10.1016/j.cceb.2016.02.001
101. Schrepfer E, Scorrano L. Mitofusins, from mitochondria to metabolism. Mol Biol Cell. (2016) 4:5. doi: 10.1186/s40170-016-0145-9
102. Xu K, Chen G, Li X, Wu X, Chang Z, Xu J, et al. Mfn2 suppresses cancer progression through inhibition of mTORC2/Akt signaling. Sci Rep. (2017) 7:41718. doi: 10.1038/srep41718

Frontiers in Endocrinology | www.frontiersin.org 9 September 2019 | Volume 10 | Article 570
Jin B, Fu G, Pan H, Cheng X, Zhou L, Lv J, et al. Anti-tumour efficacy of mitofusin-2 in urinary bladder carcinoma. Med Oncol. (2011) 28(Suppl. 1):S373–80. doi: 10.1007/s12032-010-9662-5

Wu Y, Zhou D, Xu X, Zhao X, Huang P, Zhou X, et al. Clinical significance of mitofusin-2 and its signaling pathways in hepatocellular carcinoma. World J Surg Oncol. (2016) 14:179. doi: 10.1186/s12957-016-0922-5

Zhang GE, Jin HL, Lin XK, Chen C, Liu XS, Zhang Q, et al. Anti-tumor effects of Mfn2 in gastric cancer. Int J Mol Sci. (2013) 14:13005–21. doi: 10.3390/ijms140713005

Xue R, Meng Q, Lu D, Liu X, Wang Y, Hao J. Mitofusin2 induces cell autophagy of pancreatic cancer through inhibiting the PI3K/Akt/mTOR signaling pathway. Oxid Med Cell Longev. (2018) 2018:2798070. doi: 10.1155/2018/2798070

Wang W, Liu X, Guo X, Quan H. Mitofusin-2 triggers cervical carcinoma cell Hela apoptosis via mitochondrial pathway in mouse model. Cell Physiol Biochem. (2018) 46:69–81. doi: 10.1159/000488410

Yao CH, Wang R, Wang Y, Kung CP, Patti GJ. Mitochondrial fusion supports increased oxidative phosphorylation during cell proliferation. eLife. (2019) 8:e41351. doi: 10.7554/eLife.41351

Zhao X, Tian C, Puszyk WM, Ogunwobi OO, Cao M, Wang T, et al. OPAT downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma. Lab Invest. (2013) 95:8–19. doi: 10.1038/labinvest.2012.144

Kong B, Wang Q, Fung E, Xue K, Tsang BK. P55 is required for cisplatin-induced processed of the mitochondrial fusion protein L-Opa1 that is mediated by the mitochondrial metallopeptidase Oma1 in gynecologic cancers. J Biol Chem. (2014) 289:27134–45. doi: 10.1074/jbc.M114.594812

Alavi MV. Targeted OMA1 therapies for cancer. Int J Cancer. (2019) 2019:32177. doi: 10.1002/ijc.32177

Ferreira-da-Silva A, Valacca C, Rios E, Populo H, Soares P, Sobrinho-Simoes M, et al. Mitochondrial dynamics protein Drp1 is overexpressed in oncocytic thyroid tumors and regulates cancer cell migration. PLoS ONE. (2015) 10:e0122308. doi: 10.1371/journal.pone.0122308

Fu L, Dong Q, He J, Wang X, Xing J, Wang E, et al. SIRT4 inhibits malignancy progression of NSCLCs, through mitochondrial dynamics mediated by the ERK–Drp1 pathway. Oncogene. (2017) 36:2724–36. doi: 10.1038/onc.2016.425

Smith G, Gallo G. To mdivi-1 or not to mdivi-1: is that the question? Dev Neurobiol. (2017) 77:1260–8. doi: 10.1002/dneu.22519

Sharp WW, Fang YH, Han M, Zhang HJ, Hong Z, Banathy A, et al. Dynamin-related protein 1 (Drp1)–mediated diastolic dysfunction in myocardial ischemia-reperfusion injury: therapeutic benefits of Drp1 inhibition to reduce mitochondrial fission. FASEB J. (2014) 28:316–26. doi: 10.1096/fj.12-226225

Qian W, Wang J, Roginskaya V, McDermott LA, Edwards RP, Stolz DB, et al. Novel combination of mitochondrial division inhibitor 1 (mdivi-1) and platinum agents produces synergistic pro-apoptotic effect in drug resistant tumor cells. Oncotarget. (2014) 5:4180–94. doi: 10.18632/oncotarget.1944

Bordt EA, Clerc P, Roelofs BA, Saladino AJ, Trettler L, Adam-Vizi V, et al. The putative Drp1 inhibitor mdivi-1 is a reversible mitochondrial complex 1 inhibitor that modulates reactive oxygen species. Dev Cell. (2017) 40:583–94.e6. doi: 10.1016/j.devcel.2017.02.020

Lucantoni F, Dussmann H, Prehn JHM. Metabolic targeting of breast cancer cells with the 2-deoxy-D-glucose and the mitochondrial bioenergetics inhibitor MDIVI-1. Front Cell Dev Biol. (2018) 6:113. doi: 10.3389/Fcell.2018.00113

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Dai and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.